Cell fate is tightly controlled by a continuous balance between cell survival and cell death
inducing mechanisms. B-cell lymphoma 2 (Bcl-2)-family members, composed of effectors …

Despite recent progress, acute myeloid leukemia (AML) remains a disease associated with
poor prognosis, particularly in older AML patients unfit to tolerate intensive chemotherapy …

Mutations in the receptor tyrosine kinases (RTKs) FLT3 and KIT are frequent and associated
with poor outcomes in acute myeloid leukemia (AML). Although selective FLT3 inhibitors …

We conducted a phase 1 trial assessing safety and efficacy of prophylactic maintenance
therapy with venetoclax and azacitidine (Ven/Aza) for patients with high-risk myelodysplastic …

We review the importance of monocytic differentiation and differentiation induction in non-
APL (acute promyelocytic leukemia) variants of acute myeloid leukemia (AML), a …

The combination of Venetoclax (Ven) with hypomethylating agents (HMA/Ven) is the
standard-of-care therapy for patients with newly diagnosed (ND) acute myeloid leukemia …

Acute myeloid leukemia (AML) is the most frequent leukemia in adults with a high mortality
rate. Current diagnostic criteria and selections of therapeutic strategies are generally based …

Satisfactory responses could be obtained for acute myeloid leukemia (AML) treated by
Venetoclax (VEN)-based therapy. However, there are still quite a few AML patients (AMLs) …

A thorough understanding of cell-line drug response mechanisms is crucial for drug
development, repurposing, and resistance reversal. While targeted anticancer therapies …

Myeloid malignancies such as myelodysplastic syndrome (MDS) & acute myeloid leukemia
(AML) are clonal diseases that emerge and progress due to the expansion of disease …